NWRN Relative Valuation - Newron Pharmaceuticals SpA - Alpha Spread

Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.66 CHF -3.04%
Market Cap: 145.9m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Relative Value

The Relative Value of one NWRN stock under the Base Case scenario is 4.07 CHF. Compared to the current market price of 7.66 CHF, Newron Pharmaceuticals SpA is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NWRN Relative Value
Base Case
4.07 CHF
Overvaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
17
vs Industry
11
Median 3Y
10.3
Median 5Y
9.1
Industry
2.6
Forward
6.4
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-2.3
Industry
22.9
Forward
203.5
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-3.1
Industry
17.6
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-4.7
Industry
25.2
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
1
Industry
2.2
vs History
14
vs Industry
9
Median 3Y
12.3
Median 5Y
8.4
Industry
2.7
Forward
6.9
vs History
17
vs Industry
10
Median 3Y
13.1
Median 5Y
9
Industry
5.4
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-3.7
Industry
13.9
Forward
28
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-3.7
Industry
17.3
Forward
35.3
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-3.8
Industry
16.1
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-3.8
Industry
18.8
vs History
7
vs Industry
8
Median 3Y
8.3
Median 5Y
3.4
Industry
2

Multiples Across Competitors

NWRN Competitors Multiples
Newron Pharmaceuticals SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Newron Pharmaceuticals SpA
SIX:NWRN
136.7m CHF 16 -8.9 -13.9 -13.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
843.2B USD 21.7 114.8 57.4 64.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.3 38.2 25.5 29.2
US
Johnson & Johnson
NYSE:JNJ
385.8B USD 4.5 10.1 12.4 16.1
US
Merck & Co Inc
NYSE:MRK
278.3B USD 4.5 20.3 13.7 16.8
UK
AstraZeneca PLC
NASDAQ:AZN
240.2B USD 4.9 37.3 17.1 25.6
CH
Roche Holding AG
SIX:ROG
206.1B CHF 3.5 17.9 10.1 12
CH
Novartis AG
SIX:NOVN
191.2B CHF 4.6 13.8 10.9 16.1
US
Pfizer Inc
NYSE:PFE
162B USD 2.9 -62.4 12.6 20.4
P/E Multiple
Earnings Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average P/E: 36.1
Negative Multiple: -8.9
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
114.8
425%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
38.2
90%
US
Johnson & Johnson
NYSE:JNJ
10.1
-22%
US
Merck & Co Inc
NYSE:MRK
20.3
7 419%
UK
A
AstraZeneca PLC
NASDAQ:AZN
37.3
175%
CH
Roche Holding AG
SIX:ROG
17.9
30%
CH
Novartis AG
SIX:NOVN
13.8
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -62.4
712%

See Also

Discover More
Back to Top